Literature DB >> 12232563

Oxidized low-density lipoprotein receptor LOX-1 and apoptosis in human atherosclerotic lesions.

D Y Li1, H J Chen, E D Staples, K Ozaki, B Annex, B K Singh, R Vermani, J L Mehta.   

Abstract

BACKGROUND: Lectin-like oxidized LDL receptor-1 (LOX-1), a novel receptor for oxidized low-density lipoprotein, mediates oxidized low-density lipoprotein-induced apoptosis of endothelial cells, monocyte adhesion to endothelium, and phagocytosis of aged cells. The present study examined the role of LOX-1 and apoptosis in human atherosclerotic lesions. METHODS AND
RESULTS: Grafted vein (n = 8), human carotid artery endarterectomy (n = 11), and normal human internal mammary artery (n = 8) specimens were used to study the expression of LOX-1 and apoptosis. LOX-1 expression was determined by reverse transcriptase-polymerase chain reaction, Western analysis, and immunostaining. Presence of apoptosis was determined by fluorescent in situ nick end-labeling staining and by the presence of poly (ADP-ribose) polymerase protein (an apoptotic marker). Expression of LOX-1 was significantly increased in atherosclerotic grafted vein and carotid artery specimens compared with that in normal arteries. LOX-1 was expressed in endothelial cells, macrophages, and smooth muscle cells. LOX-1 was extensively expressed in the new blood vessels in the core of advanced atherosclerotic lesions. Double immunostaining showed LOX-1 expression to be colocalized with apoptotic cells. Fluorescent in situ nick end-labeling staining showed that the apoptotic cells were present mostly in the rupture-prone regions of the atherosclerotic plaque.
CONCLUSION: These observations indicate that LOX-1 is extensively expressed in the proliferated intima of grafted veins and in advanced atherosclerotic carotid arteries. Further, LOX-1 is colocalized with apoptotic cells. These observations may relate to the phenomenon of plaque rupture, and provide targets for developing new therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12232563     DOI: 10.1177/107424840200700304

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  13 in total

1.  Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance.

Authors:  Dayuan Li; Amit R Patel; Alexander L Klibanov; Christopher M Kramer; Mirta Ruiz; Bum-Yong Kang; Jawahar L Mehta; George A Beller; David K Glover; Craig H Meyer
Journal:  Circ Cardiovasc Imaging       Date:  2010-05-04       Impact factor: 7.792

2.  Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1.

Authors:  Jens De Vos; Iris Mathijs; Catarina Xavier; Sam Massa; Ulrich Wernery; Luc Bouwens; Tony Lahoutte; Serge Muyldermans; Nick Devoogdt
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

3.  Comparative genome-wide transcriptional analysis of human left and right internal mammary arteries.

Authors:  Giovanni Ferrari; John Quackenbush; John Strobeck; Lan Hu; Christopher K Johnson; Andrew Mak; Richard E Shaw; Kathleen Sayles; Mariano E Brizzio; Alex Zapolanski; Juan B Grau
Journal:  Genomics       Date:  2014-05-20       Impact factor: 5.736

4.  Expression of transforming growth factor beta 1-related signaling proteins in irradiated vessels.

Authors:  Raimund H M Preidl; Patrick Möbius; Manuel Weber; Kerstin Amann; Friedrich W Neukam; Andreas Schlegel; Falk Wehrhan
Journal:  Strahlenther Onkol       Date:  2014-12-09       Impact factor: 3.621

Review 5.  The discovery of LOX-1, its ligands and clinical significance.

Authors:  Ryo Yoshimoto; Yoshiko Fujita; Akemi Kakino; Shin Iwamoto; Tomohide Takaya; Tatsuya Sawamura
Journal:  Cardiovasc Drugs Ther       Date:  2011-10       Impact factor: 3.727

Review 6.  Endothelium and its alterations in cardiovascular diseases: life style intervention.

Authors:  Gaia Favero; Corrado Paganelli; Barbara Buffoli; Luigi Fabrizio Rodella; Rita Rezzani
Journal:  Biomed Res Int       Date:  2014-02-26       Impact factor: 3.411

7.  Picroside II attenuates hyperhomocysteinemia-induced endothelial injury by reducing inflammation, oxidative stress and cell apoptosis.

Authors:  Yunkai Wang; Yajun Hong; Chunyu Zhang; Yunli Shen; Ye Shen Pan; Rui Zhen Chen; Qi Zhang; Yi Han Chen
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310

8.  Detection of a High Ratio of Soluble to Membrane-Bound LOX-1 in Aspirated Coronary Thrombi From Patients With ST-Segment-Elevation Myocardial Infarction.

Authors:  An-Sheng Lee; Yu-Chen Wang; Shih-Sheng Chang; Ping-Hang Lo; Chia-Ming Chang; Jonathan Lu; Alan R Burns; Chu-Huang Chen; Akemi Kakino; Tatsuya Sawamura; Kuan-Cheng Chang
Journal:  J Am Heart Assoc       Date:  2020-01-13       Impact factor: 5.501

Review 9.  Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative LDL and Potential Therapeutic Strategies.

Authors:  Der-Yuan Chen; Tatsuya Sawamura; Richard A F Dixon; José Luis Sánchez-Quesada; Chu-Huang Chen
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

10.  6-Shogaol Protects against Oxidized LDL-Induced Endothelial Injruries by Inhibiting Oxidized LDL-Evoked LOX-1 Signaling.

Authors:  Yun Kai Wang; Ya Jun Hong; Yong Hua Yao; Xiao Min Huang; Xue Bo Liu; Chun Yu Zhang; Lei Zhang; Xiaoliang Leon Xu
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.